Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 07, 2020 16:30 ET
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to 13 new employees consisting of an aggregate of 40,500 stock...
Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2019 Revenue and Initial Revenue Guidance for 2020
January 09, 2020 16:01 ET
|
Flexion Therapeutics, Inc.
Fourth-quarter 2019 revenue estimated to be approximately $23.7 millionFull-year 2019 revenue estimated to be approximately $73 million, representing year-over-year growth of more than 220%Flexion...
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 03, 2020 16:30 ET
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., Jan. 03, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to five new employees consisting of an aggregate of 17,000...
Flexion Therapeutics Announces FDA Approval of sNDA to Revise ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Product Label
December 26, 2019 16:15 ET
|
Flexion Therapeutics, Inc.
Conference call scheduled for Friday, December 27, 2019 at 8:00 a.m. ET BURLINGTON, Mass., Dec. 26, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S....
Flexion Therapeutics Enrolls First Patients in Phase 2 Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in OA of the Shoulder and Adhesive Capsulitis
December 17, 2019 07:30 ET
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the first three patients were enrolled in a clinical trial to evaluate the efficacy...
Flexion Therapeutics Announces the Retirement of Neil Bodick, M.D., Ph.D., Chief Scientific Officer and Company Co-Founder
December 10, 2019 09:00 ET
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Neil Bodick, M.D., Ph.D., Chief Scientific Officer, will retire effective January...
Flexion Therapeutics to Host Physician Event at Orthopaedic Summit 2019 Featuring Panel of Former Professional Athletes Treated With ZILRETTA® for Osteoarthritis Knee Pain
December 09, 2019 09:00 ET
|
Flexion Therapeutics, Inc.
NFL broadcaster Solomon Wilcots to go “Knee to Knee” as moderator of discussion with 1980 USA hockey team captain Mike Eruzione, NFL Hall of Fame member Rod Woodson and retired MLB player Chris...
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 06, 2019 16:30 ET
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to six new employees consisting of an aggregate of 25,300 stock...
Flexion Therapeutics Presents ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Efficacy Data at the AAHKS and ACR Annual Meetings
November 11, 2019 07:30 ET
|
Flexion Therapeutics, Inc.
Post-hoc sensitivity analysis assessed efficacy in patients who reported moderate-to-severe osteoarthritis (OA) pain prior to treatment on both ADP and WOMAC-A scalesIn this analysis of concordant...
Flexion Therapeutics Reports Third-Quarter 2019 Financial Results and Recent Business Highlights
November 07, 2019 16:01 ET
|
Flexion Therapeutics, Inc.
Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $21.8 million in Q3 representing 29% growth over Q2Full-year 2019 ZILRETTA net sales guidance...